Systemic delivery of CAT‐152, a neutralising anti‐TGF‐β2 antibody, has been shown to reduce the incidence of pathogenic fibrosis in the kidney during the acute phase of DN [61]. This evidence concerns the gene TGFB2 and liver dysplastic nodule.